Skip to main content
. 2021 Feb 12;20(2):192–194. doi: 10.4103/wjnm.WJNM_108_20

Figure 3.

Figure 3

The patient treated with gonadotropin releasing hormone analogs and restaged in January 2020 with a decrease in prostate specific antigen levels to 3.54 ng/ml from previous records. Current scans (a-d) showed increase in liver lesion, from 2.0 cm to 8.0 cm, diagnosed as focal nodular hyperplasia with stable metastatic lymph node and bone lesions from prostate cancer